Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Craig M McDonald,Eduardo Marbán,Suzanne Hendrix,Nathaniel Hogan,Rachel Ruckdeschel Smith,Michelle Eagle,Richard S Finkel,Cuixia Tian,Joanne Janas,Matthew M Harmelink,Arun S Varadhachary,Michael D Taylor,Kan N Hor,Oscar H Mayer,Erik K Henricson,Pat Furlong,Deborah D Ascheim,Siegfried Rogy,Paula Williams,Linda Marbán,HOPE-2 Study Group,Russell Butterfield,Anne Connolly,Francesco Muntoni,Nanette C Joyce,Maya Evans,Mehrdad Abedi,Prasanth Surampudi,Sanjay Jhawar,Jonathan G Dayan,Colleen Anthonisen,Erica Goude,Alina Nicorici,Omaid Sarwary,Poonam Prasad,Jayoon Baek,Andrew Newton,Hannah Johnson,Kyle Kusmik,Lauri Filar,Angie Edmondson,Irina Rybalsky,Wendy Chouteau,Anthony F Giordano,Aixa Rodriguez,Kristan Anderson,Germaine Wezel,Melisa Vega,Julie Duke,Jorge Collado,Matthew Civitello,Julie Wells,Erika Pyzik,Rebecca Rehborg,Michelle Brown,Jennifer Van Eyk,Russell G Rogers
DOI: https://doi.org/10.1016/S0140-6736(22)00012-5
2022-03-12
Abstract:Background: Cardiosphere-derived cells (CDCs) ameliorate skeletal and cardiac muscle deterioration in experimental models of Duchenne muscular dystrophy. The HOPE-2 trial examined the safety and efficacy of sequential intravenous infusions of human allogeneic CDCs in late-stage Duchenne muscular dystrophy. Methods: In this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients with Duchenne muscular dystrophy, aged 10 years or older with moderate upper limb impairment, were enrolled at seven centres in the USA. Patients were randomly assigned (1:1) using stratified permuted blocks to receive CAP-1002 (1·5 × 108 CDCs) or placebo intravenously every 3 months for a total of four infusions. Clinicians, caregivers, patients, and clinical operations personnel were fully masked to treatment groups. The primary outcome was the change in mid-level elbow Performance of Upper Limb version 1.2 (PUL 1.2) score at 12 months, assessed in the intention-to-treat population. Safety was assessed in all individuals who received an investigational product. This trial is registered with ClinicalTrials.gov, NCT03406780. Findings: Between March 1, 2018, and March 31, 2020, 26 male patients with Duchenne muscular dystrophy were enrolled, of whom eight were randomly assigned to the CAP-1002 group and 12 to the placebo group (six were not randomised due to screening failure). In patients who had a post-treatment PUL 1.2 assessment (eight in the CAP-1002 group and 11 in the placebo group), the mean 12-month change from baseline in mid-level elbow PUL1.2 favoured CAP-1002 over placebo (percentile difference 36·2, 95% CI 12·7-59·7; difference of 2·6 points; p=0·014). Infusion-related hypersensitivity reactions without long-term sequelae were observed in three patients, with one patient discontinuing therapy due to a severe allergic reaction. No other major adverse reactions were noted, and no deaths occurred. Interpretation: CAP-1002 cell therapy appears to be safe and effective in reducing deterioration of upper limb function in patients with late-stage Duchenne muscular dystrophy. Various measures of cardiac function and structure were also improved in the CAP-1002 group compared with the placebo group. Longer-term extension studies are needed to confirm the therapeutic durability and safety of CAP-1002 beyond 12 months for the treatment of skeletal myopathy and cardiomyopathy in Duchenne muscular dystrophy. Funding: Capricor Therapeutics.